Trending...
- Virginia National Bank Names New President
- Ellucian Named to GSV EdTech 150 List for 2022
- Axiros Proudly Announces the Availability of a New Release AXESS 4.0
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. ("Aditxt") (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the launch of an underwritten public offering.
Dawson James Securities, Inc. is acting as sole book-running manager for the offering.
The proposed offering of the common stock and warrants described above is being made pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-257645), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on July 13, 2021, and the base prospectus contained therein. Such shares of common stock and warrants may be offered only by means of a prospectus, including a prospectus supplement.
A prospectus supplement and accompanying prospectus related to the offering of common stock will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering of common stock and warrants may be obtained, when available, by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 101 North Federal Highway, Suite 600, Boca Raton, FL, 33432, cwachowiz@dawsonjames.com or toll free at 866.928.0928.
More on virginir.com
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Aditxt
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements in this press release include, without limitation, the ability of the Company to close the offering. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
More on virginir.com
Contacts
Aditxt, Inc.
ir@aditxt.com
Dawson James Securities, Inc. is acting as sole book-running manager for the offering.
The proposed offering of the common stock and warrants described above is being made pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-257645), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on July 13, 2021, and the base prospectus contained therein. Such shares of common stock and warrants may be offered only by means of a prospectus, including a prospectus supplement.
A prospectus supplement and accompanying prospectus related to the offering of common stock will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering of common stock and warrants may be obtained, when available, by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 101 North Federal Highway, Suite 600, Boca Raton, FL, 33432, cwachowiz@dawsonjames.com or toll free at 866.928.0928.
More on virginir.com
- CIS Secure Announces TSG Certified Cisco DX80
- Edge Computing Tech Company StrongNode.io Enters the World of Crypto Mobile Apps in Partnership with Dopamine
- ATA Begins Final Round of America's Road Team Selection
- Life of Consequences Feature Film Screening Scheduled
- Dominion Energy Virginia Prepares for Weekend Winter Storm, Urges Customers to Prepare as Well
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Aditxt
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements in this press release include, without limitation, the ability of the Company to close the offering. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
More on virginir.com
- Xcelerate Solutions Announces New Partnership with the University of the District of Columbia
- 456 Collectors Club Presale Sold Out: Worlds First NFT Art Club Makes History
- Magnolia Green welcomes Magnolia Academy Children's Center to the community
- Karen Benedict Ranked No. 1 on Kehrer Bielan's Top Directors List
- Furnace Part Source Teams Up With Extend To Offer Product Protection Program
Contacts
Aditxt, Inc.
ir@aditxt.com
Filed Under: Business
0 Comments
Latest on virginir.com
- N Home Needs: Start Your Cooking Journey With The Proper Tools And Utensils
- Workplace Health Scientists Urge Employers: Regardless of Supreme Court Ruling on Vax Mandates Employers and Employees Can Take Critical Steps to Reduce the Risk of COVID-19 in the Workplace
- PRA Group Employees Exceed Pledging Goal for 2021-22 United Way Campaign
- Arizona Attorney and Navy Veteran Wife Launch New Youtube Channel About Auto Injury Law
- The rise of vacation rentals in Emerald Coast, Florida over traditional hotels
- Leading Realtor in Southeastern Indiana Opens New Brokerage
- Marketing and Communications Executive Vanessa Birch Joins Itero Group
- Bloomberg Tax Announces Enhancements to Tax Provision Solution
- BPD: Making the Complex Simple
- Expel Adds Growth Veterans to Leadership Team, Continues Momentum Following Fundraise and $1B+ valuation
- The Role Of Stress In Human Health And Immunity
- Intelsat Continues Investment in Global 5G Software-Defined Network with Acquisition of Two Software-Defined Satellites from Thales Alenia Space
- Stride Inc. Second Quarter Fiscal Year 2022 Earnings Conference Call Details
- Markel names Tyler Brown, Managing Director, Investments
- Fast Mobile Home Loans Expands into Washington, Creates New Home Lending Product
- Tulsa Recycling Professional Robert Pickens Honored with Lifetime Achievement Award
- Virginia National Bank Names New President
- 5 Forces That Will Drive the Dollar in 2022 and Beyond
- TownePlace Suites Monroe, Michigan Opens
- A Modern Twist to the Old-Fashioned Spelling Bee